The nation of Zimbabwe has turned down a substantial US health deal valued at $367m (272 million pounds) spanning five years due to the United States' demand for sensitive data.
This move came to light after a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government spokesman has since explained that the United States was requesting biological samples for research and commercial purposes while was not willing to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for further negotiations to reach a deal suitable to both sides so the nation's critical HIV programme can be sustained.
Wider Implications
This rejection comes after a comparable case in Kenya, where a high court halted a related deal with the US following concerns were raised about the safety of citizens' health data.
After resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking direct bilateral agreements to enhance transparency and accountability.
According to reports, Sixteen nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy via American-funded initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to surrender its biological resources and data for a long time, without any equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"Put simply, our country would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our citizens should a new pandemic emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of one-on-one deals were disrupting systems previously set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This mechanism is designed to ensure that when a country provides its information, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our US partners on how future co-operation could be designed in a way that honours the sovereignty and interests of each country."
Health Experts Reaction
A leading public health body stated it understood the government's concerns, but suggested that talks need to persist considering much of the nation's Aids initiatives depended on international support.
"In cases where technical issues exist, including those relating to information security or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," it commented.
The situation highlights the complex challenges between receiving much-needed international aid and protecting a country's data in an increasingly data-driven world.